NKTR - Nektar Therapeutics Stock Price, Fair Value and News

1.38USD+0.01 (+0.73%)Market Closed

Market Summary

USD1.38+0.01

Market Closed

0.73%

NKTR Stock Price

View Fullscreen

NKTR RSI Chart

NKTR Valuation

Market Cap

253.4M

Price/Earnings (Trailing)

-1.44

Price/Sales (Trailing)

2.81

EV/EBITDA

-1.21

Price/Free Cashflow

-1.34

NKTR Price/Sales (Trailing)

NKTR Profitability

EBT Margin

-195.21%

Return on Equity

-139.08%

Return on Assets

-44.5%

Free Cashflow Yield

-74.65%

NKTR Fundamentals

NKTR Revenue

Revenue (TTM)

90.2M

Rev. Growth (Yr)

0.21%

Rev. Growth (Qtr)

-9.4%

NKTR Earnings

Earnings (TTM)

-176.2M

Earnings Growth (Yr)

73.14%

Earnings Growth (Qtr)

11.73%

Breaking Down NKTR Revenue

Last 7 days

-0.7%

Last 30 days

26.6%

Last 90 days

4.6%

Trailing 12 Months

170.6%

How does NKTR drawdown profile look like?

NKTR Financial Health

Current Ratio

6.1

NKTR Investor Care

Buy Backs (1Y)

2.96%

Diluted EPS (TTM)

-0.91

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	90.2M	0	0	0
2023	88.8M	87.7M	88.3M	90.1M
2022	103.1M	96.3M	95.0M	92.1M
2021	126.0M	105.5M	100.4M	101.9M
2020	137.0M	162.5M	163.3M	152.9M
2019	1.2B	119.1M	120.6M	114.6M
2018	529.1M	750.5M	971.9M	1.2B
2017	131.3M	133.1M	249.7M	307.7M
2016	180.9M	191.0M	167.4M	165.4M
2015	289.7M	283.9M	211.0M	230.8M
2014	145.7M	140.3M	212.3M	200.7M
2013	86.2M	96.4M	138.9M	148.9M
2012	78.1M	84.5M	75.8M	81.2M
2011	137.1M	111.9M	101.0M	71.5M
2010	93.7M	115.5M	137.3M	159.0M
2009	0	0	0	71.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

CEO	Mr. Howard W. Robin
WEBSITE	nektar.com
INDUSTRY	Biotechnology
EMPLOYEES	216

Nektar Therapeutics Frequently Asked Questions

What is the ticker symbol for Nektar Therapeutics? What does NKTR stand for in stocks?

NKTR is the stock ticker symbol of Nektar Therapeutics. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nektar Therapeutics (NKTR)?

As of Fri Jul 26 2024, market cap of Nektar Therapeutics is 253.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NKTR stock?

You can check NKTR's fair value in chart for subscribers.

Is Nektar Therapeutics a good stock to buy?

The fair value guage provides a quick view whether NKTR is over valued or under valued. Whether Nektar Therapeutics is cheap or expensive depends on the assumptions which impact Nektar Therapeutics's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NKTR.

What is Nektar Therapeutics's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, NKTR's PE ratio (Price to Earnings) is -1.44 and Price to Sales (PS) ratio is 2.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NKTR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Nektar Therapeutics's stock?

In the past 10 years, Nektar Therapeutics has provided -0.188 (multiply by 100 for percentage) rate of return.